Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 5,059 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: CNS
Interventions: E2006, Placebo comparator; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Culver City, California • Glendale, California

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions: Enzalutamide; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: Male only
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 9
States / cities: Anchorage, Alaska • Detroit, Michigan • New York, New York + 5 more

Conditions: Obesity
Interventions: NT-0796, Placebo; Drug
Lead sponsor: Rezera (formerly NodThera Limited); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Mesa, Arizona • Hialeah, Florida • Jacksonville, Florida + 6 more

Conditions: Healthy Participants
Interventions: E2730, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Obstructive Sleep Apnea
Interventions: AD182, AD504, Placebo, Polysomnography; Drug · Diagnostic Test
Lead sponsor: Apnimed; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cancer, Non-small Cell Lung Cancer
Interventions: XL147 (SAR245408), Erlotinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Triple Negative Breast Cancer
Interventions: GTx-024; Drug
Lead sponsor: GTx; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Fort Lauderdale, Florida • Lakeland, Florida • Miami, Florida + 4 more

Conditions: Healthy
Interventions: Ashwagandha (Withnia somnifera); Dietary Supplement
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alzheimer s Disease
Interventions: Terazosin (Hytrin), Placebo; Drug · Other
Lead sponsor: Qiang Zhang; Other
Eligibility: 50 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Adenocarcinoma of the Prostate, Stage III Prostate Cancer, Stage IV Prostate Cancer, Recurrent Prostate Cancer
Interventions: antineoplaston A10, antineoplaston AS2-1, bicalutamide, flutamide, leuprolide acetate, alternative product therapy, antiandrogen therapy, biological therapy, biologically based therapies, cancer prevention intervention, complementary and alternative therapy, differentiation therapy, endocrine therapy, hormone therapy; Drug · Procedure
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Pain, Headache
Interventions: Open-label placebo pills; Dietary Supplement
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19, Corona Virus Infection, Wuhan Coronavirus, Prophylaxis, Healthcare Worker, Sars-CoV2, Hydroxychloroquine
Interventions: Hydroxychloroquine, Placebo; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 1,700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Lafayette, Louisiana

Conditions: Healthy
Interventions: Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule, 5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Gastrointestinal Neoplasms
Interventions: Ulixertinib, Hydroxychloroquine; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Depression
Interventions: Psilocybin (Usona Institute); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Low Back Pain
Interventions: Metaxalone, Tizanidine, Baclofen, Ibuprofen 600 mg, Educational intervention; Drug · Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Heroin Dependence, Opioid-Related Disorders, Substance-Related Disorders
Interventions: naltrexone, Placebo comparator; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Clostridium Difficile Infection
Interventions: FZ002, Placebo for FZ002; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Pharmacokinetics, Drug Interactions
Interventions: Dasatinib ASD, Omeprazole 40 MG; Drug
Lead sponsor: Xspray Pharma AB; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions: Milk thistle (MT), Placebo, Lifestyle Modification, Fibroscan; Drug · Behavioral · Device
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 9 Years to 22 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Post-operative Dental Pain
Interventions: Test acetaminophen, Commercial acetaminophen, Commercial ibuprofen, Placebo; Drug
Lead sponsor: Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division; Industry
Eligibility: 17 Years to 50 Years
Enrollment: 664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Essential Tremor
Interventions: 1-Octanol; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 21 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma, Penile Squamous Cell Carcinoma
Interventions: rigosertib; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 13
States / cities: Sacramento, California • Stanford, California • Aurora, Colorado + 10 more

Conditions: Healthy
Interventions: Indoximod HCL (F2) tablets, Indoximod base formulation, Placebo; Drug · Other
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Secaucus, New Jersey

Search by objective public record fields.

2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy Participants

Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea

Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors

Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

Safety of Ashwagandha (Withania Somnifera) Root Extract

Terazosin And Metabolic Engagement in Alzheimer's Disease

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Placebo Impacts Sleep and Pain Modulation in Chronic Pain

Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)

Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension

Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas

Psilocybin-Assisted Therapy as a Treatment for Depression

Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain

Addition of Naltrexone to Methadone Taper

A Safety Trial to Evaluate an Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

Milk Thistle Clinical Trial in Pediatric NAFLD

Randomized, Double-Blind, Single-Dose, Efficacy and Safety Study of Test Acetaminophen Tablet in Postoperative Dental Pain

Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor

Oral Rigosertib for Squamous Cell Carcinoma

Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers